You are here

Pfizer boosts China presence with US$350m biotech plant

Facility to be completed in 2018, will make biologics and cheaper versions


PFIZER Inc will invest US$350 million in eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.

The new

Market voices on: